Similarly, combining HIF-1-mediated ectoenzyme ENTPD2 inhibitors with anti-CTLA-4/PD-1 ICIs significantly increased T-cell infiltration in hepatocellular carcinoma tumors and extended survival in tumor-bearing mice (149). This evidence concerns the gene HIF1A and neoplasm.